Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

John G. Gribben; Wojciech Jurczak; Ryan W. Jacobs; Sebastian Grosicki; Krzysztof Giannopoulos; Tomasz Wrobel; Syed F. Zafar; Jennifer L. Cultrera; Suman Kambhampati; Alexey Danilov; John M. Burke; Jerome Goldschmidt; Douglas F. Beach; Scott F. Huntington; Javier Pinilla Ibarz; Jeff P Sharman; Tanya Siddiqi; Danielle M. Brander; John M. Pagel; Kathryn S. Kolibaba; Monika Dlugosz-Danecka; Nilanjan Ghosh; Peter Sportelli; Hari P. Miskin; Owen A. O'Connor; Michael S. Weiss; Ian W. Flinn

doi:10.1182/BLOOD-2020-134783

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

John G. Gribben
, Wojciech Jurczak
, Ryan W. Jacobs
, Sebastian Grosicki
, Krzysztof Giannopoulos
, Tomasz Wrobel
, Syed F. Zafar
, Jennifer L. Cultrera
, Suman Kambhampati
, Alexey Danilov
, John M. Burke
, Jerome Goldschmidt
, Douglas F. Beach
, Scott F. Huntington
, Javier Pinilla Ibarz
, Jeff P Sharman
, Tanya Siddiqi
, Danielle M. Brander
, John M. Pagel
, Kathryn S. Kolibaba

Monika Dlugosz-Danecka, Nilanjan Ghosh, Peter Sportelli, Hari P. Miskin, Owen A. O'Connor, Michael S. Weiss, Ian W. Flinn

Queen Mary University of London
Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland
Department of Hematology, Lymphoma Division, Levine Cancer Institute, Charlotte, NC
Department of Hematology and Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland
Medical University of Lublin
Wrocław Medical University
Sarah Cannon Research Institute
Oregon Health & Science University
US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, CO
Blue Ridge Cancer Centers / US Oncology Research, Blacksburg, VA
Pennsylvania Hospital
Yale Cancer Center
Department of Immunology, Moffitt Cancer Center, Tampa, FL
Willamette University
City of Hope National Medical Center
Duke University
Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
Compass Oncology / US Oncology Research, Vancouver, WA
TG Therapeutics, Inc., New York, NY

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Blood
Volume	136
DOIs	https://doi.org/10.1182/BLOOD-2020-134783
State	Published - Nov 5 2020
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1182/BLOOD-2020-134783License: Unspecified

Cite this

Gribben, J. G., Jurczak, W., Jacobs, R. W., Grosicki, S., Giannopoulos, K., Wrobel, T., Zafar, S. F., Cultrera, J. L., Kambhampati, S., Danilov, A., Burke, J. M., Goldschmidt, J., Beach, D. F., Huntington, S. F., Ibarz, J. P., Sharman, J. P., Siddiqi, T., Brander, D. M., Pagel, J. M., ... Flinn, I. W. (2020). Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study. Blood, 136. https://doi.org/10.1182/BLOOD-2020-134783

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study. / Gribben, John G.; Jurczak, Wojciech; Jacobs, Ryan W. et al.
In: Blood, Vol. 136, 05.11.2020.

Research output: Contribution to journal › Article › peer-review

Gribben, JG, Jurczak, W, Jacobs, RW, Grosicki, S, Giannopoulos, K, Wrobel, T, Zafar, SF, Cultrera, JL, Kambhampati, S, Danilov, A, Burke, JM, Goldschmidt, J, Beach, DF, Huntington, SF, Ibarz, JP, Sharman, JP, Siddiqi, T, Brander, DM, Pagel, JM, Kolibaba, KS, Dlugosz-Danecka, M, Ghosh, N, Sportelli, P, Miskin, HP, O'Connor, OA, Weiss, MS & Flinn, IW 2020, 'Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study', Blood, vol. 136. https://doi.org/10.1182/BLOOD-2020-134783

@article{ff319984942e43bb964c0500148ae82d,

title = "Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Na{\"i}ve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study",

author = "Gribben, \{John G.\} and Wojciech Jurczak and Jacobs, \{Ryan W.\} and Sebastian Grosicki and Krzysztof Giannopoulos and Tomasz Wrobel and Zafar, \{Syed F.\} and Cultrera, \{Jennifer L.\} and Suman Kambhampati and Alexey Danilov and Burke, \{John M.\} and Jerome Goldschmidt and Beach, \{Douglas F.\} and Huntington, \{Scott F.\} and Ibarz, \{Javier Pinilla\} and Sharman, \{Jeff P\} and Tanya Siddiqi and Brander, \{Danielle M.\} and Pagel, \{John M.\} and Kolibaba, \{Kathryn S.\} and Monika Dlugosz-Danecka and Nilanjan Ghosh and Peter Sportelli and Miskin, \{Hari P.\} and O'Connor, \{Owen A.\} and Weiss, \{Michael S.\} and Flinn, \{Ian W.\}",

note = "Oral and Poster Abstracts Oral 642. CLL: Therapy, excluding Transplantation II Biological, antibodies, Diseases, CLL, Lymphoma (any), Non-Biological, Therapies, Combinations, Lymphoid Malignancies John G. Gribben, MD, DSc, FRCP, FMedSci, FRCPath 1, Wojciech Jurczak, MD, PhD 2, Ryan Jacobs, MD 3, Sebastian Grosicki, MD, PhD 4, Krzysztof Giannopoulos, MD, PhD 5, Tomasz Wrobel, MD PhD 6, Syed F.",

year = "2020",

month = nov,

day = "5",

doi = "10.1182/BLOOD-2020-134783",

language = "American English",

volume = "136",

journal = "Blood",

publisher = "American Society of Hematology",

}

TY - JOUR

T1 - Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

AU - Gribben, John G.

AU - Jurczak, Wojciech

AU - Jacobs, Ryan W.

AU - Grosicki, Sebastian

AU - Giannopoulos, Krzysztof

AU - Wrobel, Tomasz

AU - Zafar, Syed F.

AU - Cultrera, Jennifer L.

AU - Kambhampati, Suman

AU - Danilov, Alexey

AU - Burke, John M.

AU - Goldschmidt, Jerome

AU - Beach, Douglas F.

AU - Huntington, Scott F.

AU - Ibarz, Javier Pinilla

AU - Sharman, Jeff P

AU - Siddiqi, Tanya

AU - Brander, Danielle M.

AU - Pagel, John M.

AU - Kolibaba, Kathryn S.

AU - Dlugosz-Danecka, Monika

AU - Ghosh, Nilanjan

AU - Sportelli, Peter

AU - Miskin, Hari P.

AU - O'Connor, Owen A.

AU - Weiss, Michael S.

AU - Flinn, Ian W.

N1 - Oral and Poster Abstracts Oral 642. CLL: Therapy, excluding Transplantation II Biological, antibodies, Diseases, CLL, Lymphoma (any), Non-Biological, Therapies, Combinations, Lymphoid Malignancies John G. Gribben, MD, DSc, FRCP, FMedSci, FRCPath 1, Wojciech Jurczak, MD, PhD 2, Ryan Jacobs, MD 3, Sebastian Grosicki, MD, PhD 4, Krzysztof Giannopoulos, MD, PhD 5, Tomasz Wrobel, MD PhD 6, Syed F.

PY - 2020/11/5

Y1 - 2020/11/5

UR - https://ash.confex.com/ash/2020/webprogram/Paper134783.html

U2 - 10.1182/BLOOD-2020-134783

DO - 10.1182/BLOOD-2020-134783

M3 - Article

VL - 136

JO - Blood

JF - Blood

ER -

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

Disciplines

Access to Document

Other files and links

Cite this